Bicycle Therapeutics, ThromboGenics deal

Bicycle granted ThromboGenics exclusive rights to develop and commercialize bicyclic peptide inhibitors against a target involved in ophthalmic diseases like diabetic macular edema (DME). The target is undisclosed but ThromboGenics said it is involved in vascular permeability. Bicycle and ThromboGenics will collaborate on preclinical development, and ThromboGenics will be responsible for subsequent development and commercialization of selected compounds. Bicycle will receive an undisclosed upfront fee and is eligible for undisclosed milestones, plus royalties. The partners could not be reached for details. ...